Glucagon-like peptide-1 and control of insulin secretion.

Details

Serval ID
serval:BIB_E8655404BB95
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Glucagon-like peptide-1 and control of insulin secretion.
Journal
Diabète et Métabolisme
Author(s)
Thorens B.
ISSN
0338-1684[print], 0338-1684[linking]
Publication state
Published
Issued date
12/1995
Volume
21
Number
5
Pages
311-318
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Abstract
Although glucose is the major regulator of insulin secretion by pancreatic beta cells, its action is modulated by several neural and hormonal stimuli. In particular, hormones secreted by intestinal endocrine cells stimulate glucose-induced insulin secretion very potently after nutrient absorption. These hormones, called gluco-incretins or insulinotropic hormones, are major regulators of postprandial glucose homeostasis. The main gluco-incretins are GIP (gastric inhibitory polypeptide or glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like polypeptide-1). The secretion of GIP, a 42 amino acid polypeptide secreted by duodenal K cells, is triggered by fat and glucose. GIP stimulation of insulin secretion depends on the presence of specific beta-cell receptors and requires glucose at a concentration at least equal to or higher than the normoglycaemic level of approximately 5 mM. GIP accounts for about 50% of incretin activity, and the rest may be due to GLP-1 which is produced by proteolytic processing of the preproglucagon molecule in intestinal L cells. GLP-1 is the most potent gluco-incretin characterized so far. As with GIP, its stimulatory action requires a specific membrane receptor and normal or elevated glucose concentrations. Contrary to GIP, the incretin effect of GLP-1 is maintained in non-insulin-dependent diabetic patients. This peptide or agonists of its beta-cell receptor could provide new therapeutic tools for the treatment of Type II diabetic hyperglycaemia.
Keywords
Animals, Diabetes Mellitus, Type 2/physiopathology, Gastric Inhibitory Polypeptide/physiology, Glucagon/physiology, Glucagon/secretion, Glucagon-Like Peptide 1, Humans, Insulin/secretion, Peptide Fragments/physiology, Peptide Fragments/secretion, Protein Precursors/physiology, Protein Precursors/secretion, Receptors, Glucagon/chemistry, Receptors, Glucagon/metabolism, Secretory Rate/physiology, Signal Transduction/physiology
Pubmed
Web of science
Create date
24/01/2008 14:41
Last modification date
20/08/2019 17:11
Usage data